Mark Leach, MD
Family Medicine · Palmyra, PANPI 1619932936
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,825 of the $10,093 with a category attached, or 87.4%. It is spread thinly across 41 manufacturers, the largest accounting for just 13.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,754, 2.4 times the $1,139 reported in 2019. Among family medicine clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 566 payments — averaging $17.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- GSK$1K
- Shionogi Inc$1K
- AstraZeneca$995
- Novo Nordisk$804
- Lilly USA, LLC$600
- plus $4K from 35 others
What the payments were for
- Consulting fees$1,13811%
- Food & beverage$8,82587%
- Education$1301%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,093 in reported general payments places this provider in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 209 | $181,502 |
| OzempicSemaglutide | 86 | $108,480 |
| JardianceEmpagliflozin | 98 | $100,226 |
| TrulicityDulaglutide | 54 | $70,036 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 76 | $63,795 |
| JanuviaSitagliptin Phosphate | 49 | $55,338 |
| FarxigaDapagliflozin Propanediol | 76 | $53,129 |
| JanumetSitagliptin Phos/Metformin Hcl | 39 | $46,690 |
| TradjentaLinagliptin | 45 | $42,511 |
| XareltoRivaroxaban | 41 | $42,269 |
| GlyxambiEmpagliflozin/Linagliptin | 56 | $41,300 |
| Breo ElliptaFluticasone/Vilanterol | 84 | $38,444 |
| RybelsusSemaglutide | 28 | $28,540 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 17 | $24,945 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 27 | $23,313 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi, Synjardy Xr, Stiolto Respimat | $449 | $214,078227 claims |
| PfizerEliquis | $396 | $181,502209 claims |
| Novo NordiskOzempic, Rybelsus | $804 | $137,020114 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $1,210 | $123,963206 claims |
| MerckJanuvia, Janumet | $123 | $102,02988 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $600 | $91,39875 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $995 | $68,916100 claims |
| Johnson & JohnsonXarelto | $323 | $42,26941 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $207 | $23,31327 claims |
| AbbVieSynthroid | $1,331 | $5,102119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Palmyra
- Neil SkolnikJenkintown$904K
- Lisa EspinozaNew Hope$722K
- Christopher Varacallodu Bois$627K
- Paul DoghramjiCollegeville$617K
- Brian DeyarminBethel Park$491K
- Nathan BennettPittsburgh$465K
- Gary OwensGlen Mills$404K
- Mary ZakutneyIrwin$393K
- H WilkinsSellersville$380K
- Deborah WittPhiladelphia$226K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.